Vanucizumab, referred to as 80 -600, represents a cutting-edge engineered protein specifically designed to vascular endothelial growth factor A . This powerful agent operates by attaching to VEGF-A, effectively preventing its interaction with its receptors and subsequently decreasing angiogenesis—the development of new tiny vessels. Its key thera